
According to reports from LiveMint, Alembic reported consolidated net profit of ₹67.57 crore for Q2 FY27, representing a decline of 11.2% year-on-year from ₹76.06 crore in the corresponding quarter last year. Revenue from operations fell significantly by 45.9% YoY to ₹30.25 crore in Q2 FY27, compared with ₹55.86 crore in the year-ago period. On a sequential basis, revenue declined from ₹48.74 crore in Q1 FY27. Total income stood at ₹101.80 crore, down 15.7% from ₹120.78 crore in Q2 FY26, which included other income of ₹71.55 crore. However, net profit showed a substantial sequential improvement from ₹15.70 crore in the June quarter to ₹67.57 crore in Q2 FY27.
As reported by LiveMint, Alembic shares surged more than 15% following the Q2 FY27 results announcement. The stock has demonstrated strong momentum with gains of 20.29% over the past week and 27.11% in the last two weeks. Over the past month, the stock has advanced 8.44% and over the past three months, it has risen 27.16%. Over a six-month period, it has gained 13.53%, taking its year-to-date gains to 5.78%. The stock opened at ₹100.65 on the BSE and touched an intraday high of ₹114.25 per share, while reaching an intraday low of ₹99.63 per share. Latest data shows the stock moved up 10.14% from its previous close of ₹99.15, with the current trading price at ₹109.20.
According to Gaurav Arora, Head of Research at SAHI, as reported by LiveMint, Alembic is witnessing a sharp V-shaped recovery supported by strong trading volumes. The stock gained 9.5% in the day's session and moved decisively above its 20-day and 50-day exponential moving averages (EMAs), indicating strong buying interest. Arora noted that the stock faces immediate resistance in the ₹115–117 zone, with an inverse head-and-shoulders pattern forming on the weekly chart. While the technical setup remains strong, a sustained move above these resistance levels is necessary to confirm further upside, he added.
As reported by LiveMint, Alembic Limited is part of the historic Alembic Group and operates as a subsidiary of Nirayu Private Limited. The company operates across three key business segments: real estate, active pharmaceutical ingredients (APIs) and power generation. Its real estate business focuses on residential and commercial developments, property leasing and project management, while its pharmaceutical division manufactures and markets fermentation- and chemistry-based APIs. The company also operates co-generation and wind power assets. The company has a market capitalization of ₹2,821.52 crore and operates within the diversified sector, with a market cap rank of 18 within its segment.